Sanofi nabs EU approval for first treatment of rare blood-clotting disorder

Sep 04, 2018

Sanofi has been granted approval in Europe for a rare blood-clotting disorder treatment using nanobodies.

The European Commission has granted marketing authorization for Cablivi (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi is the first therapeutic specifically indicated for the treatment of aTTP.

The U.S Food & Drug Administration had previously granted the drug a ‘Fast Track’ designation and has an expected target date of Feb. 2019.

Caplacizumab, to be marketed as Cablivi, was developed by Belgium company Ablynx which was acquired by Sanofi earlier this year for $4.53 billion.

Read the full release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments